 Orphazyme AS NASDAQ: ORPH has been notified by the Committee for Medicinal Products for Human Use CHMP of a negative trend vote on arimoclomol application following an Oral Explanation. The application covers arimoclomol for Niemann-Pick disease type C NPC, a rare genetic. 